Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
=== Laboratory tests === Laboratory tests including urea and creatinine levels, liver enzymes, glucose, thyroid function, full blood count, and clotting tests. The analysis of serum and urine for presence of monoclonal immunoglobulin is also done through immunofixation for detection of the monoclonal band. Presence of the monoclonal band would be consistent with light chain amyloidosis. For light chain amyloidosis, serum immunoglobulin free light chain assay can be used for diagnosis and following of the amyloidosis. In light-chain amyloidosis, a low paraprotein level can be present.
== The importance of tightly controlled relative humidity == Maintaining high relative humidity (RH) in modified atmosphere packaging is important because it "results in reduced transpiration of water from the produce, thereby reducing wilting, shriveling, and loss of firmness. The accumulation of vapor in the packaging depends on the rate of water loss from the product, its surface area, the water vapor transmission rate (WVTR) of the film, and the external environment temperature." "The RH in most sealed packaging is near the saturation level. Therefore, even very small fluctuations in temperature during storage or shipment may result in water condensation on the surface of both film and produce. Condensed water on the produce surface may adversely affect the gas exchange, leading to an unfavorable internal atmosphere." Even more detrimental may be the enhancement of produce decay, and physiological processes such as regrowth. In addition, certain human pathogens may proliferate when in-pack atmosphere contains high humidity and low O2.
=== BOC (1968-2006) === BOC Group's purchase of Edwards in 1968 was followed by international expansion, particularly into Asia, and investment at the Crawley, Eastbourne, Shoreham and Burgess Hill sites. In 1984, Edwards developed and patented the first practical high vacuum dry (no-oil) pump. The design was taken up by the fast-growing semiconductor manufacturing market. In 1992, Edwards purchased Electrotech Ltd's semiconductor manufacturing exhaust gas management systems. It was based in Nailsea before moving to Clevedon, UK to add to Edwards' semiconductor manufacturing environmental abatement technology. Four years later in 1996, new facilities in Burgess Hill are inaugurated. In 1997, BOC merged its electronics gases business with Edwards as BOC Edwards. In the same year, the company purchased Systems Chemistry Inc, a supplier of management systems for ultrapure chemicals used in semiconductor manufacturing, from Submicron Systems Corp of Allentown (USA). It became Edwards' chemical management division. Allentown, USA. It became Edwards' chemical management division. In 1999, Edwards acquired the Minneapolis-based division of FSI International Inc, for US$38 million. This was followed by the purchase of the Hick Hargreaves vacuum ejector and deaerator units; Wilhelm Klein GmbH; Stokes piston pump operations, and Hibon Inc for £12.8 million from Smiths Group. In 2002, they purchased Seiko Industry's turbomolecular pump manufacturing business for £70 million.
== June 17, 1915 (Thursday) == Second Battle of Artois — French forces launched a second attack on Vimy Ridge but failed to take it. British pilot Reginald Warneford died along with American journalist Henry Beach Newman after crashing a new Farman biplane during takeoff from Buc, France, just shortly after a ceremony in Paris in which he received the French Legion of Honour for shooting down a German airship. Former U.S. President William Howard Taft became president of the League to Enforce Peace when it was established during a peace convention at Independence Hall in Philadelphia. Other founding members of the organization included Elihu Root, Alexander Graham Bell, Rabbi Stephen Samuel Wise, U.S. Chamber of Commerce executives James Gibbons and Edward Filene, Harvard University President A. Lawrence Lowell, and former U.S. Cabinet member and diplomat Oscar Straus. The baseball stadium Bosse Field officially opened in Evansville, Indiana, the first municipally owned stadium in the United States. It is the third oldest operating ballpark after Fenway Park and Wrigley Field. Born: Mario Echandi Jiménez, 33rd President of Costa Rica from 1958 to 1962; in San José, Costa Rica (d. 2011) David "Stringbean" Akeman, American country musician, member of band for the TV variety show Hee Haw and a member of the Grand Ole Opry; in Annville, Kentucky, United States (d. 1973, murdered) Died: Thomas Jordan Jarvis, 79, American politician, 44th Governor of North Carolina (b. 1836)
TATA box Also Goldberg-Hogness box. A highly conserved non-coding DNA sequence containing a consensus of repeating T and A base pairs that is commonly found in promoter regions of genes in archaea and eukaryotes. The TATA box often serves as the site of initiation of transcription or as a binding site for transcription factors.
Sources: en.wikipedia.org
It’s a fight for our national security." He advocated for a special inspector general to monitor the aid given to Ukraine following Russia's invasion. Kennedy expressed concern that money was being misspent, saying, "Ukraine is not without flaws. We've heard several unsettling reports of bad actors exploiting our generosity… We trust that our friends in Ukraine take corruption seriously. We must verify, too."
If chronic gynecomastia does not respond to medical treatment, surgical removal of glandular breast tissue is usually required. The American Board of Cosmetic Surgery reports surgery is the "most effective known treatment for gynecomastia". Surgical treatment should be considered if the gynecomastia persists for more than 12 months, causes distress (i.e. physical discomfort or psychological distress), and is in the fibrotic stage. In adolescent males, it is recommended that surgery is postponed until puberty is completed (penile and testicular development should reach Tanner scale Stage V). Surgical approaches to the treatment of gynecomastia include subcutaneous mastectomy, liposuction-assisted mastectomy, laser-assisted liposuction, and laser-lipolysis without liposuction. Complications of mastectomy may include hematoma; surgical wound infection; breast asymmetry; changes in sensation in the breast; necrosis of the areola or nipple; seroma; noticeable or painful scars; and contour deformities. In 2019, 24,123 male patients underwent surgical treatment for gynecomastia in the United States, accounting for a 19% increase since 2000. Thirty-five percent of those patients were between the ages of 20 and 29, and 60% were younger than age 29 at the time of the operation. At an average surgeon's fee of $4,123, gynecomastia surgery was also the 11th most costly male cosmetic surgery of 2019.
=== Oxytalan fibers === Oxytalan fibers are unique to the PDL and are elastic in nature. It inserts into cementum and runs in two directions: parallel to root surface and oblique to root surface. The function is thought to maintain the patency of blood vessels during occlusal loading. Further research is needed to determine the function of oxytalan fibers.
As a result, whey protein is now widely used in sports and recovery drinks, meal-replacement beverages, medical nutrition, and other products, completing its transition from a dairy by-product into a major beverage ingredient.
Sources: en.wikipedia.org
Barbara Walters Interview with General Schwarzkopf, Coalition commander in the Persian Gulf War (Video: ABC, 1991) Gulf War Discussion from the Dean Peter Krogh Foreign Affairs Digital Archives Historical Context from the Dean Peter Krogh Foreign Affairs Digital Archives CBC Digital Archives – The 1991 Gulf War Master Index of Desert Storm Oral History Interviews Archived 31 December 2010 at the Wayback Machine by the United States Army Center of Military History Bibliography of the Desert Shield and Desert Storm compiled by the United States Army Center of Military History (via Wayback Machine) Desert Shield/Desert Storm Photographs Archived 17 October 2015 at the Wayback Machine US Army Heritage and Education Center, Carlisle, Pennsylvania Persian Gulf War 20th Anniversary of Desert Storm in Photos Air Force and Air Defense of Iraq before the war (not translated) exact list of the technical details Liberating Kuwait United States Marine Corps Friendly-fire Incidents Archived 1 June 2013 at the Wayback Machine – www.gulflink.osd.mil Operations Desert Shield and Desert Storm: Valorous Unit Award Citations by the United States Army Center of Military History
Bicinchoninic acid () or BCA is a weak acid composed of two carboxylated quinoline rings. It is an organic compound with the formula (C9H5NCO2H)2. The molecule consists of a pair of quinoline rings, each bearing a carboxylic acid group. Its sodium salt forms a purple complex with cuprous ions. Bicinchoninic acid is most commonly employed in the bicinchoninic acid (BCA) assay, which is used to determine the total concentration of protein in a solution. Bicinchoninic acid is used to detect the presence of cuprous ions, due to its purple coloration via a biuret reaction. In this assay, two molecules of bicinchoninic acid chelate a single Cu+ ion, forming a purple water-soluble complex that strongly absorbs light at 562 nm.
Dimethyltryptamine (DMT), also known as N,N-dimethyltryptamine (N,N-DMT), is a serotonergic hallucinogen and investigational drug of the tryptamine family that occurs naturally in many plants and animals. DMT is used as a psychedelic drug and prepared by various cultures for ritual purposes as an entheogen. DMT has a rapid onset, intense effects, and a relatively short duration of action. For those reasons, DMT was known as the "businessman's trip" during the 1960s in the United States, as a user could access the full depth of a psychedelic experience in considerably less time than with other substances such as LSD or psilocybin mushrooms. DMT can be inhaled or injected and its effects depend on the dose, as well as the mode of administration. When inhaled or injected, the effects last about five to fifteen minutes. Effects can last three hours or more when orally ingested along with a monoamine oxidase inhibitor (MAOI), such as the ayahuasca brew of many native Amazonian tribes. DMT induces intense, often indescribable subjective experiences involving vivid visual hallucinations, altered sensory perception, ego dissolution, and encounters with seemingly autonomous entities. DMT is generally considered non addictive with low dependence and having little to no tolerance build-up with short-acting routes, but it may cause acute psychological distress or cardiovascular effects, especially in predisposed individuals. DMT was first synthesized in 1931.
Narrated by Paul Brightwell, produced by David Sington, directed by David McNab, made by Dox Productions 4 March The Engines That Came in from the Cold, about the Russian N1 rocket with an unexpected and surprising outcome to the documentary, and a reference to the 1963 book The Spy Who Came in from the Cold; George Mueller, head of Apollo programme from 1963 to 1969; Charles Vick of the Federation of American Scientists; Sergei Korolev, chief designer at OKB-1; Vasily Mishin, deputy chief designer at OKB-1, had done calculations showing that to get a cosmonaut on the Moon, it required a 100 tonne vehicle in orbit, which would require a 2,000 tonne vehicle at lift-off; Valentin Anisimov, chief designer at Kuznetsov Design Bureau, and how Korolev approached the Kuznetsov company, to make the new rocket engines for the proposed N1 rocket launcher, but it was too new and large to develop from scratch, so thirty pre-existing engines would be deployed, and the pre-burner which powered the rocket pumps would become a closed cycle, to improve power by 25%, but this was vastly untested; the first twelve launches would be uncrewed, followed by two test crewed launches, and the Soviet limited budget meant that development was not at a sufficient stage (that NASA would have arrived at) before the launches were carried out; this first uncrewed launch took place on 21 February 1969, and one minute into the flight, the rocket exploded; the N1 had a thrust of 4,500 tonnes at launch; the N1 second launch took place on 3 July 1969, after the engine control system was modified, and a few seconds after launch the engine cut out, and the whole N1 launcher fell onto the launch pad, causing total catastrophic results - this explosion stopped any further Soviet Union attempt to reach the Moon with a crewed rocket, the launch pad damage was unrecoverable; two weeks later Apollo 11 landed on the Moon; the N1 next launch was on 26 June 1971, with a rebuilt launch pad, and this launch exploded one minute into the flight; the fourth launch of the N1 on 23 November 1972 exploded two minutes into the flight; by the mid-1970s the Kuznetsov NK-33 closed-cycle engine, for the N1, had been sufficiently tested in its development lifetime; the Soviet Moon mission was around four years behind NASA, and when the engines were finally sufficiently tested, the whole Soviet Moon programme was stopped in 1974; any N1 engines and systems were instructed to be removed, to eliminate its knowledge; only in the early 1990s did knowledge of the N1 first appear; Bob Ford of Lockheed Martin and Bill Hoffman of Aerojet; Kuznetsov had nonetheless kept around sixty NK-33 engines in Samara - the home of Soviet rocketry, and wanted to show these engines to visitors from Aerojet; after a successful test of an NK-33 at Sacramento in October 1995, the NK-33 was developed into the RD-180, which powered the American Lockheed Martin Atlas III rocket; John Karas, of Lockheed Martin, at the first launch of an American rocket, on 24 May 2000 of the Eutelsat 36A satellite, that was powered by a Russian engine - the RD-180, which was twice as powerful as the NK-33, and one engine could replace five engines of the previous Atlas II; Vladimir Chvanov and Boris Katorgin, designers at NPO Energomash; the American rocket engineers had viewed the closed-cycle method as far too dangerous, and it was dangerous, but Russian engineers had developed new stainless steel alloys to largely overcome this danger. Narrated by Jaye Griffiths, produced by Hamish Barbour, directed by, made by Ideal World Productions 17 June The Day the Oceans Boiled, about the Earth's environment; 55 million years ago, the Earth was 6C hotter than it is now, with no ice caps, and trees grew at Antarctica, the temperature became 8C hotter, known as the Paleocene-Eocene Thermal Maximum; mammals shrunk in how large; since 55m years ago, carbon dioxide has been absorbed by plants, cooling the Earth; climate models were derived from weather forecast models; Peter Cox (climatologist) of the Met Office, and carbon sinks, and how each year 6 billion tonnes of carbon dioxide enters the atmosphere, but the effect appears to be only from around 3 billion tonnes; Antonio Nobre of the National Institute of Amazonian Research - he found that the Amazon forest, and its 500 million hectares of trees, was a much bigger carbon sink than presumed - it could be absorbing three-quarters of the carbon dioxide of all the world's vehicles; the Greenland Ice Sheet Project, and Geoffrey Hargreaves at the National Science Foundation Ice Core Facility (NICL) in Colorado, and ice cores from the Vostok Station; the Earth has warmed and cooled in a 100,000 years cycle; the Met Office model predicted that after 2050, due to shortage of rainfall seasons, the Amazon forest would not act as a carbon sink; Carlos Nobre (scientist) and dry seasons, and the possible danger of fire, caused by changes in the tropical climate; Richard Corfield (scientist); Philip D. Gingerich of the University of Michigan; Santo Bains was researching the Paleocene-Eocene boundary, so went to the Gulf Coast Repository, and looked at Core 690 drilled by JOIDES Resolution of the Ocean Drilling Program from the Weddell Sea, and concluded that rapid changes in Earth temperature came from methane clathrates (methane hydrates); geologist Euan Nisbet; the Earth returned to lower temperatures after 60,000 years. Narrated by Matthew Zajac, directed by David Sington, made by Dox Productions 24 June The Fish That Time Forgot, about the coelacanth; Margery Courtney Latimer in 1938 of the Natural History Museum, London, and a fish caught at East London; J. L. B. Smith, from Grahamstown, of Rhodes University; the American Museum of Natural History; evolutionary biologist John McCusker; the Comoro Islands, run by the French, near Madagascar, where another fish was found in 1952; Mike Ruton; Robin Stobbs; the JAGO (German research submersible) and Hans Fricke of the Max Planck Institute for Behavioral Physiology, who found a live fish on 17 January 1987; Susan Jewett of the National Museum of Natural History in Washington; on 30 July 1998, a live female fish is found on a beach in Indonesia by Mark Erdmann. Narrated by Robert Lindsay, produced by Ron Ackerman, directed by Celia Lowenstein, made by Diverse Productions with Nova 8 July The Secret Life of the Mouse, about the laboratory mouse; zoologist Sam Berry of UCL; mouse geneticist Jo Peters of MRC Harwell; Irving Weissman; most genetic research is done with mice, with 25 million a year; Steve Brown, Director of MRC Harwell; the mouse has 99.9% of the genes of humans; the Jackson Laboratory has 1m mice and around 1,000 human staff, with 2,500 strains of mice, who have mouse models of human diseases, and mice breed much quicker than humans do; Beverly Paigen; in one year, there are three generations of mice; twenty Nobel prizes have depended on mouse research; Cliffe Rosen of the Maine Center of Osteoporosis Research; scientists want mutant mice for each gene; Charles Vacanti of the University of Massachusetts Medical School, whose cartilage research led to a mouse having an artificial cartilage human ear grown on its back; Philip Leder of Harvard Medical School, who placed a patent on a mouse; a fluorescent mouse; Hank Greely of Stanford University; it ends with the opening lines from A Tale of Two Cities. Narrated by Stephen Fry, produced by David Paterson, directed by Kevin Hull, made by BOA 2001. The documentary has overtones of the music video of the 2001 Where's Your Head At, made in the same year as the documentary 15 July Saving the Leaning Tower, a documentary chronicling the dramatic rescue of one of the world’s most iconic landmarks. By the late 1980s, the Leaning Tower of Pisa was on the brink of collapse, its southward tilt increasing steadily and threatening catastrophic failure. Alarm spread after the sudden fall of a medieval bell tower in Pavia in 1989, which convinced authorities to close Pisa’s monument to the public. An international committee of engineers, geologists, and historians was formed to save the tower, among them British civil engineer John Burland. Through detailed investigation, the team uncovered the structural weaknesses behind the marble façade and the unstable soils beneath Pisa. Computer models showed the tower should already have collapsed. Temporary steel tendons and 600 tonnes of lead counterweights prevented immediate disaster, but the tower’s fate remained uncertain. Burland proposed a novel, delicate solution: controlled “soil extraction” below the northern side to allow the tower to gently tilt back to stability. The project was plagued by risks, political disputes, and near-disasters, including the “Black September” of 1995, when freezing the foundations caused the tower to lurch alarmingly. Despite opposition, the soil extraction method was eventually approved in 1998. Over two years, engineers removed around 70 tonnes of soil, gradually reducing the lean by half a meter without visible alteration to the monument. By June 2001, the tower had been successfully stabilized, restored to the inclination it had in the 18th century, and reopened to the public. The operation was hailed as one of the greatest feats of modern civil engineering, ensuring the survival of Pisa’s unique heritage for centuries to come. The documentary presents not only the technical challenges but also the cultural, historical, and emotional significance of preserving this medieval masterpiece. 13 October Battle of the Robots: The Hunt for AI, about the work of Hugo de Garis, Rodney Brooks, and Steve Grand (roboticist); the documentary opens with the archetypal and iconic robot HAL 9000 from the 1968 2001: A Space Odyssey (film) and The Blue Danube; Igor Aleksander, who worked in neural systems at Imperial College London, and his views on the likelihood of computational intelligence; Dan Dennett; British roboticist Steve Grand, of North Somerset made the world's first AI computer game Creatures in 1996, and was designing a glider that could teach itself; Blay Whitby of the University of Sussex; the MIT Computer Science and Artificial Intelligence Laboratory and Brian Scassellati, who was designing a social robot called Cog (project); Belgian Walter De Brouwer of Starlab in Belgium; engineer Kevin Warwick of the University of Reading at the 2001 Royal Society Prizes for Science Books (Aventis Prize for Science Books), won by Robert Kunzig. Narrated by Patrick Forbes, produced by Nicolas Kent 28 October Bioterror, an Equinox Special, about biological weapons, with Judith Miller and her 2001 book Germs: Biological Weapons and America's Secret War; Robert Kadlec of the National War College; science writer William Broad; the ATCC in Manassas, Virginia; microbiologist William C. Patrick III; the 2001 anthrax attacks; microbiologist Richard O. Spertzel; geneticist Matthew Meselson; Gennady Lepyoshkin, Director from 1987 to 2001 of a Russian secret biological research site; Jonathan B. Tucker; Chris Shays; Andrew C. Weber; Sergei Popov (bioweaponeer) had worked at the State Research Center for Applied Microbiology in Obolensk, Moscow Oblast. Produced by Matthew Collins, directed by Kirk Wolfinger, made by WGBH. Shown on Tuesday 20 November 2001 on The Nature of Things in Canada, and on Nova, and on Nova on Tuesday 13 November 2001
In most developed countries, there are two main types of lab processing the majority of medical specimens. Hospital laboratories are attached to a hospital, and perform tests on their patients. Private (or community) laboratories receive samples from general practitioners, insurance companies, clinical research sites and other health clinics for analysis. For extremely specialised tests, samples may go to a research laboratory. Some tests involve specimens sent between different labs for uncommon tests. For example, in some cases it may be more cost effective if a particular laboratory specializes in a less common tests, receiving specimens (and payment) from other labs, while sending other specimens to other labs for those tests they do not perform. In many countries there are specialized types of medical laboratories according to the types of investigations carried out. Organisations that provide blood products for transfusion to hospitals, such as the Red Cross, will provide access to their reference laboratory for their customers. Some laboratories specialize in Molecular diagnostic and cytogenetic testing, in order to provide information regarding diagnosis and treatment of genetic or cancer-related disorders.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。